Department of Nuclear Medicine, Ludwig-Maximilians-University, Munich, Germany.
J Nucl Med. 2011 Nov;52(11):1679-83. doi: 10.2967/jnumed.111.089276. Epub 2011 Oct 5.
We hypothesized that (68)Ga-DOTATATE uptake of neuroendocrine tumors is sensitive to therapy with a nonradioactive somatostatin analog.
(68)Ga-DOTATATE PET/CT was used to examine 105 patients, 35 of whom had been pretreated with long-acting octreotide. The maximum standardized uptake value (SUV(max)) of target tissues, as well as metastases, was compared between the groups of patients with (group 1) and without (group 2) octreotide treatment.
The SUV(max) of the spleen and liver was significantly lower in group 1 than in group 2 (both P < 0.001). There were no significant group differences in SUV(max) for primary tumors (28.6 ± 6.8 vs. 32.9 ± 31.5) or metastases in the liver (27.2 ± 14.8 vs. 25.7 ± 10.7), lymph nodes (41.4 ± 19.5 vs. 25.0 ± 6.3), or skeleton (39.5 ± 22.0 vs. 15.4 ± 7.8). In 9 patients available for intraindividual comparison, tumor uptake was unaffected by treatment with somatostatin analogs (21.7 vs. 20.6; P = 0.93).
Treatment with a long-acting somatostatin analog did not significantly reduce (68)Ga-DOTATATE binding in neuroendocrine tumors but tended to improve the tumor-to-background ratio.
我们假设神经内分泌肿瘤对非放射性生长抑素类似物治疗的（68）Ga-DOTATATE 摄取具有敏感性。
使用（68）Ga-DOTATATE PET/CT 检查了 105 例患者，其中 35 例患者接受了长效奥曲肽治疗。比较了两组患者（有奥曲肽治疗组[组 1]和无奥曲肽治疗组[组 2]）中靶组织（包括转移灶）的最大标准化摄取值（SUV(max)）。
与组 2 相比，组 1 患者的脾脏和肝脏 SUV(max)显著降低（均 P < 0.001）。两组患者原发肿瘤（28.6 ± 6.8 比 32.9 ± 31.5）或肝脏转移灶（27.2 ± 14.8 比 25.7 ± 10.7）、淋巴结（41.4 ± 19.5 比 25.0 ± 6.3）或骨骼（39.5 ± 22.0 比 15.4 ± 7.8）的 SUV(max)均无显著组间差异。9 例患者可进行个体内比较，肿瘤摄取未受生长抑素类似物治疗的影响（21.7 比 20.6；P = 0.93）。
长效生长抑素类似物治疗并未显著降低神经内分泌肿瘤的（68）Ga-DOTATATE 结合，但可能会改善肿瘤与背景的比值。
